Invested in the Future of Cardiovascular Medicine

Our purpose is driven by our vision to stop cardiovascular disease from being a leading cause of death worldwide. Amarin is a global pharmaceutical company developing new treatments to fight against cardiovascular disease. Amarin is relentless in its pursuit of scientific breakthroughs that can lead to revolutionary treatments to create a healthier world. Find out more about who we are, what we stand for and how we are making a difference in the lives of patients.

Show all

Quarterly Earnings Q2 2026

Learn more

Latest Events

Click a link below for access to our events.

Learn more

Latest News From Amarin

From research results, financial toolkits and webcasts to important investor information and financial governance. Find out the latest financial news about Amarin in these publications.

Learn More

Jul 29, 2026

Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence

Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA ’s U.S. Market Share, an Improved OPEX Profile, and Positive Cash Flow Generation DUBLIN, Ireland and
Read more
Jul 15, 2026

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report second quarter 2026 financial results and conduct a conference call on
Read more
Jun 30, 2026

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape 

Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides DUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a
Read more

Investor inquiries

For corporate governance, analyst coverage, stock information, secretarial matters and other investor-related queries, please use the Contact form:

Contact Us
Financial Information

Balancing Passion with Resolution

Learn more about Amarin’s revenue, expenses, profit and loss, as well as a comprehensive overview of the company’s financial health.

Learn More

 

Sign-Up for Email Alerts

Amarin Logo
You are about to leave the Amarincorp.com website
You have selected a link that will take you away from the amarincorp.com website. Amarin is not responsible for the content of the alternate website. Privacy and security policies of the alternate website may differ from those practiced by Amarin.

By clicking on the continue button below, you acknowledge the previous statement and will be taken to the linked site. If you want to remain at this site, select the cancel button. Thank you.